<?xml version="1.0" encoding="UTF-8"?>
<p>HBV reactivation (HBVr) is a well-recognized complication of immunosuppressive treatment in cancer, rheumatic diseases, and organ transplantation.
 <sup>
  <xref rid="bibr9-1759720X20912646" ref-type="bibr">9</xref>
 </sup> It typically occurs in patients with chronic HBV infection [Hepatitis B surface Antigen (HBsAg) positive], but, less commonly, it can complicate immunosuppressive treatment in patients with resolved HBV infection [HBsAg negative/antibody against Hepatitis B core antigen (anti-HBc) positive]. HBVr is usually defined as: a rise in serum HBV-DNA compared with baseline levels or detection of HBV DNA if undetectable at baseline, or reverse seroconversion (re-emergence) of HBsAg from negative to positive (see 
 <xref rid="table2-1759720X20912646" ref-type="table">Table 2</xref> for full definitions).
 <sup>
  <xref rid="bibr10-1759720X20912646" ref-type="bibr">10</xref>,
  <xref rid="bibr11-1759720X20912646" ref-type="bibr">11</xref>
 </sup> Factors that influence the risk of HBVr are related to the patient, the virus, and the type and duration of immunosuppression used (
 <xref rid="table3-1759720X20912646" ref-type="table">Table 3</xref>).
 <sup>
  <xref rid="bibr12-1759720X20912646" ref-type="bibr">12</xref>
 </sup>
</p>
